Competition & Peer Data API & CSV Delivery

Kairos Pharma Ltd's Competitiveness

Name: Kairos Pharma Ltd Competitors and Peer Comparison
Creator: CSIMarket
License: https://csimarket.com/help/terms-of-use

A competitive positioning analysis and financial ratio benchmarking of Kairos Pharma Ltd (KAPA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q2 2026

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/KAPA/competitors                    

                        https://api.csimarket.com/api/v1/companies/KAPA/relationships                    

                        https://api.csimarket.com/api/v1/companies/KAPA/similar                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AI Integration via MCP

Connect Claude, ChatGPT, or any MCP-compatible AI assistant directly to this data.

Kairos Pharma Ltd's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity	Profitable	Expanding	Above Industry Growth	Distressed
Kairos Pharma Ltd	-	-	-	Yes
Similar-Size Competitors (10)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

KAPA Stock Performance relative to its Competitors

KAPA Competitors (weighted) Percent change over the selected range

Kairos Pharma Ltd's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.

Similar-Size
(1 of 10)

Entity	TTM Share Price Return (group: median)	vs U.S.A. 500
Kairos Pharma Ltd	57.50 %	Outperformed
Competitors combined (0)	40.4%	63.2%
High-Confidence Competitors (0)	40.4%	63.2%
Similar-Size Competitors (10)	40.4%	63.2%
Similar Growth & Profitability (0)	40.4%	63.2%

Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Kairos Pharma Ltd's competitor groups requires a Commercial License.

Unlock Commercial Access

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

KAPA Stock Performance relative to Similar-Size Competitors

KAPA Similar-Size Competitors (equal-weighted, 10) Percent change over the selected range

Kairos Pharma Ltd's Comment on Competition and Industry Peers

The competitive landscape includes therapeutics targeting GITR, primarily consisting of antibodies that bind the receptor. The small molecule drug under discussion differs by binding to the GITR ligand and stabilizing the receptor trimer, which may result in enhanced signaling and reduced side effects compared to antibody treatments.

Competitor data is not yet available for Kairos Pharma Ltd.